Skip to main content

Tabrecta Side Effects

Generic name: capmatinib

Medically reviewed by Drugs.com. Last updated on Jan 15, 2021.

Note: This document contains side effect information about capmatinib. Some of the dosage forms listed on this page may not apply to the brand name Tabrecta.

For the Consumer

Applies to capmatinib: oral tablet

Side effects requiring immediate medical attention

Along with its needed effects, capmatinib (the active ingredient contained in Tabrecta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking capmatinib:

More common

  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • chest pain
  • chills
  • clay colored stools
  • cough
  • dark urine
  • decreased or loss of appetite
  • difficult or labored breathing
  • fever
  • general feeling of discomfort or illness
  • headache
  • itching
  • nausea and vomiting
  • rapid weight gain
  • skin rash
  • stomach pain or tenderness
  • swelling of the feet or lower legs
  • thickening of bronchial secretions
  • tightness in the chest
  • tingling of the hands or feet
  • unusual weight gain or loss
  • unusual tiredness or weakness
  • yellow eyes or skin

Less common

Incidence not known

  • Increased sensitivity of the skin to sunlight
  • redness or other discoloration of the skin
  • severe sunburn

Side effects not requiring immediate medical attention

Some side effects of capmatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to capmatinib: oral tablet

Hematologic

Very common (10% or more): Lymphocytes decreased (44%), hemoglobin decreased (24%), leukocytes decreased (23%)[Ref]

Musculoskeletal

Very common (10% or more): Noncardiac chest pain (e.g., chest discomfort, musculoskeletal chest pain, noncardiac chest pain, chest pain) (15%), back pain (14%)[Ref]

Metabolic

Very common (10% or more): Albumin decreased (68%), creatinine increased (62%), alanine aminotransferase increased (37%), alkaline phosphatase increased (32%), amylase increased (31%), gamma-glutamyltransferase increased (29%), lipase increased (26%), aspartate aminotransferase increased (25%), sodium decreased (23%), phosphate decreased (23%), glucose decreased (21%), weight loss (10%)[Ref]

Respiratory

Very common (10% or more): Dyspnea (24%), cough (16%)

Common (1% to 10%): ILD/pneumonitis[Ref]

Other

Very common (10% or more): Peripheral edema (e.g., peripheral swelling, peripheral edema, fluid overload) (52%), fatigue/asthenia (32%), pyrexia/increased body temperature (14%)[Ref]

Renal

Very common (10% or more):

Common (1% to 10%): Acute kidney injury (including renal failure)[Ref]

Dermatologic

Common (1% to 10%): Pruritus (allergic and generalized), cellulitis, urticaria[Ref]

Gastrointestinal

Very common (10% or more): Nausea (44%), vomiting (28%), constipation (18%), diarrhea (18%)

Common (1% to 10%): Acute pancreatitis[Ref]

References

1. "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals, East Hanover, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.